Unternehmens-Profil
GSK plc is a global biopharma company dedicated to uniting science, technology, and talent to get ahead of disease. Its primary purpose is to positively impact the health of 2.5 billion people by the end of the decade through innovative prevention and treatment strategies. The company focuses its research and development efforts on four key therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases, leveraging advanced tools like digital biological twins and organoids to accelerate drug discovery. GSK plc emphasizes long-acting therapies for HIV, novel treatments for asthma and nasal polyps, and efforts to make cancer curable, while addressing global health challenges such as high-burden infectious diseases in lower-income countries. Committed to responsibility, it pursues net zero emissions, nature-positive goals, affordable access programs, and inclusive research to meet diverse patient needs. With a significant U.S. presence employing around 15,000 people across commercial, R&D, manufacturing, and corporate functions, GSK plc plays a pivotal role in advancing biopharmaceutical innovation and health security worldwide.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 18,585 GBP· Stand 07.05.2026
News · GlaxoSmithKline plc
- Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
- The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
- Big Pharma M&A set for mega year as patent expiries drive deal urgency
- Why GSK (GSK) is a Top Value Stock for the Long-Term
- JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited